Analyst Upgrades This Radiology Stock, Expects Promising 2023 Ahead
Raymond James upgraded Radnet Inc (NASDAQ:RDNT) from Market Perform to Outperform and a price target of $30 following 4Q22 results that came in…
RadNet Q4 Adj EPS $0.11 Misses $0.15 Estimate, Sales $383.90M Beat $347.27M Estimate
RadNet (NASDAQ:RDNT) reported quarterly adjusted earnings of $0.11 per share which missed the analyst consensus estimate of $0.15 by 26.67 percent. This is a 15.38 percent decrease over earnings of $0.13 per share from
Radiology Imaging Associates Launches The Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered By Artificial Intelligence
Radiology Imaging Associates, a division of RadNet, Inc. (NASDAQ:RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service (https://myEBCDmammo.com), which works
RadNet’s Artificial Intelligence Subsidiary, DeepHealth, Announces FDA Clearance Of Its Third AI Mammography Product
RadNet, Inc. (NASDAQ:RDNT), today announced that its subsidiary DeepHealth, Inc., a leading developer of artificial intelligence (AI) for mammography interpretation, has received FDA clearance of its mammography density
Delaware Imaging Network, A Division Of RadNet, Inc. Launches The Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered By Artificial Intelligence
Delaware Imaging Network, a division of RadNet, Inc. (NASDAQ:RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service (https://myEBCDmammo.com), which works in
RadNet Forecasts Lower Profits In 2022 Due To Rising Costs, Labor Shortage
RadNet Inc (NASDAQ:RDNT) reported Q3 adjusted EPS of $0.09, down from $0.21 a year ago and missing the consensus of…
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.